GlassScriptPhysician profile
Carol A Wiggins
NPI 1952339756
$4,829.75
in general payments reported to CMS, 2019-2025
29 companies · $867 in 2025
The $867 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $299 · 2021: $663 · 2022: $847 · 2023: $707 · 2024: $931 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $563.39 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.00 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $411.78 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $391.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $386.34 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $375.48 | 2021-2025 | Takhzyro, Cuvitru |
| Pfizer INC. | $293.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $274.71 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $235.88 | 2021-2025 | Xembify |
| Biocryst US Sales Co., LLC | $211.27 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $193.26 | 2019-2025 | Ruconest |
| Kaleo, INC. | $168.96 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $151.79 | 2020-2022 | |
| Genentech USA, INC. | $130.67 | 2019-2024 | Xolair |
| Optinose US, INC. | $103.44 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82.70 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $57.07 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.67 | 2019-2020 | |
| Blueprint Medicines Corporation | $39.55 | 2022-2023 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $27.00 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $25.08 | 2025 | Dawnzera |
| Incyte Corporation | $24.45 | 2024 | Opzelura |
| Adma Biomanufacturing LLC | $23.84 | 2021 | |
| Cycle Pharmaceuticals INC | $22.78 | 2025 | Sajazir |
| Alk-Abello, INC | $19.59 | 2019 | |
| Shire North American Group INC | $19.49 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.28 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $16.80 | 2020 | |
| Lilly USA, LLC | $16.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.